MOS and TPL2 are upstream signal molecules of ERK1/2, and TPL2 overexpression is involved in resistance to imatinib in CD34+ CML cells.22, 23. Here, MAPK3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.